Procalcitonin
EstablishedProcalcitonin helps distinguish bacterial from viral/non-infectious causes of inflammation and guides antibiotic stewardship decisions.
Procalcitonin rises specifically with bacterial infections, unlike some other inflammation markers that rise with almost anything. Hospitals increasingly use it to help decide when it's safe to stop antibiotics, though it's meant to support a doctor's judgment, not replace it.
Procalcitonin (PCT) is a precursor peptide of calcitonin that rises specifically in response to bacterial infection and systemic inflammation, distinguishing it from CRP's more general inflammatory elevation pattern.
Elevated procalcitonin supports bacterial (versus viral) infection and correlates with severity in sepsis; it's most useful for guiding antibiotic stewardship decisions, including when to safely discontinue antibiotics in patients improving clinically.
Measured via immunoassay; serial procalcitonin-guided protocols are used in many hospitals to support antibiotic discontinuation decisions in lower respiratory tract infections and sepsis, generally showing reduced antibiotic duration without worsening outcomes across multiple clinical trials.
Procalcitonin-guided algorithms are incorporated into some sepsis and antibiotic stewardship protocols, though guidelines emphasize it should support, not replace, overall clinical judgment, since procalcitonin can be elevated in some non-infectious conditions (major trauma, surgery, some cancers) and can remain low in certain localized or early bacterial infections.
Procalcitonin-guided protocols reduce antibiotic duration in several clinical trials without worsening patient outcomes.
- General critical care and infectious disease reference literature on procalcitonin-guided antibiotic stewardship protocols.